Apellis Pharmaceuticals Inc (NAS:APLS)
$ 40.07 -0.26 (-0.64%) Market Cap: 4.86 Bil Enterprise Value: 4.65 Bil PE Ratio: 0 PB Ratio: 18.22 GF Score: 38/100

Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 05:20PM GMT
Release Date Price: $30.45 (-3.64%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst

Good afternoon. I'm Andrea Tan from the biotechnology team at Goldman Sachs, and it's my pleasure to host a fireside chat with Apellis management team. With us, we have Cedric Francois, Co-Founder and CEO; Adam Townsend, Chief Commercial Officer; and Tim Sullivan, Chief Financial Officer. Thanks so much for joining us today.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Thank you so much, Andrea.

Questions & Answers

Andrea R. Tan;Cedric Francois
Goldman Sachs Group, Inc., Research Division - Research Analyst;Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director<

Great. So maybe to start, just as a high level overview. If you could provide one of the complement cascade and why targeting C3 is so important? And then maybe provide some thoughts on how to think about that in the context of competitors who are looking at C5 inhibitors?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot